Needham & Company Reiterates Strong Buy Rating on Myriad Genetics (MYGN) as Final LCD Issued for myPath Melanoma
Go back to Needham & Company Reiterates Strong Buy Rating on Myriad Genetics (MYGN) as Final LCD Issued for myPath Melanoma| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 4.54 +0.48 (11.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.06 | 52 Week High | $45.34 | |||
| Open | $4.16 | 52 Week Low | $15.92 | |||
| Day High | $4.59 | P/E | 1.95 | |||
| Day Low | $4.16 | EPS | $2.33 | |||
| Volume | 2,283,751 | |||||
